ANDA 207260, held by Xiromed. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 207260 (Norethindrone Acetate And Ethinyl Estradiol), held by Xiromed, was first approved by FDA on Feb 2, 2017, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 2, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norethindrone Acetate And Ethinyl Estradiol0.0025MG;0.5MG · tablet;oral | Ethinyl Estradiol; Norethindrone Acetate | Discontinued |
| Feb 16, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 26, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 26, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 2, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters